Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 1,795 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 1,795 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10. Following the completion of the sale, the insider directly owned 34,826 shares in the company, valued at $1,064,979.08. This trade represents a 4.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

• On Wednesday, March 18th, Barry Ticho sold 6,686 shares of Stoke Therapeutics stock. The stock was sold at an average price of $31.34, for a total transaction of $209,539.24.
• On Tuesday, March 17th, Barry Ticho sold 6,164 shares of Stoke Therapeutics stock. The stock was sold at an average price of $33.01, for a total transaction of $203,473.64.
• On Thursday, March 19th, Barry Ticho sold 1,461 shares of Stoke Therapeutics stock. The stock was sold at an average price of $29.99, for a total transaction of $43,815.39.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $29.46 on Thursday. Stoke Therapeutics, Inc. has a 1-year low of $10.64 and a 1-year high of $40.22. The firm has a market capitalization of $1.83 billion, a P/E ratio of -10.48 and a beta of 1.17. The company’s 50-day moving average is $32.70 and its 200 day moving average is $32.32.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.01. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. The company had revenue of $6.23 million for the quarter, compared to analyst estimates of $6.48 million. Research analysts anticipate that Stoke Therapeutics, Inc. will post -3.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

STOK has been the topic of a number of research reports. Wall Street Zen lowered shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Needham & Company LLC raised their target price on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Guggenheim initiated coverage on shares of Stoke Therapeutics in a research report on Thursday, February 5th. They set a “buy” rating and a $60.00 target price on the stock. Wolfe Research initiated coverage on shares of Stoke Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $40.00 target price on the stock. Finally, BTIG Research reaffirmed a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a research report on Monday, May 11th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $41.83.

Institutional Trading of Stoke Therapeutics

A number of hedge funds have recently added to or reduced their stakes in STOK. Kestra Advisory Services LLC purchased a new position in Stoke Therapeutics during the fourth quarter valued at approximately $26,000. KBC Group NV purchased a new position in Stoke Therapeutics during the first quarter valued at approximately $36,000. Harbour Investments Inc. increased its holdings in Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares during the period. Generali Investments Management Co LLC purchased a new position in Stoke Therapeutics during the third quarter valued at approximately $41,000. Finally, BNP Paribas Financial Markets increased its holdings in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.